| Date | Title | Description | Source |
| 09.04.2024 | Merck Life Science gets new MD | Merck has appointed Dhananjay Singh as Managing Director of Merck Life Science, in India. He takes o... | thehindubu... |
| 01.04.2024 | Submission of Leqembi® (lecanemab-irmb) sBLA for IV maintena... | Submission of Leqembi® (lecanemab-irmb) sBLA for IV maintenance dosing for the treatment of early Al... | news.cisio... |
| 22.03.2024 | Lecanemab deliberations at the CHMP regarding the Marketing ... | Lecanemab deliberations at the CHMP regarding the Marketing Authorisation Application in the EU have... | news.cisio... |
| 19.03.2024 | Professor Lars Lannfelt, awarded Fondation Recherche Alzheim... | Professor Lars Lannfelt, awarded Fondation Recherche Alzheimer’s European Grand Prix for his contrib... | news.cisio... |
| 13.03.2024 | После вмешательства генпрокурора РФ 68 южноуральцев обеспече... | - | kommersant... |
| 13.03.2024 | AI Impact Tour arrives in Boston on March 27: A focus on dat... | Join leaders in Boston on March 27 for an exclusive night of networking, insights, and conversation.... | venturebea... |
| 12.03.2024 | How Do Companies Avert Further Frustration among Neurologist... | Spherix Global Insights captures neurologists’ reactions within 48 hours of these pivotal announceme... | einpresswi... |
| 11.03.2024 | New data on lecanemab presented at the 2024 AD/PD™ congress... | New data on lecanemab presented at the 2024 AD/PD™ congress
Mon, Mar 11, 2024 08:00 CET Report this ... | news.cisio... |
| 08.03.2024 | From the Beach to the Boardroom: Unispace's 'Art for Impact'... | The collaboration produced 30 unique tapestries for the offices of Unispace clients like Zoom Video ... | einpresswi... |
| 08.03.2024 | FDA delays action on Lilly's Alzheimer's drug | The Food and Drug Administration is asking outside advisors to review the safety and efficacy of an ... | axios.com/... |
| 07.03.2024 | SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on... | - | globenewsw... |
| 06.03.2024 | New Biomarker Data Add Further Evidence Supporting the Poten... | - | globenewsw... |
| 04.03.2024 | Biogen Highlights New Data at the International Conference o... | New data advances understanding of new approaches to treating Alzheimer’s disease
Research on diseas... | einpresswi... |
| 19.07.2023 | Eisai Presents Latest Analysis of Lecanemab’s Effect on Biom... | /EIN News/ -- Further Phase 3 analysis shows benefits of lecanemab on both amyloid-beta and tau, two... | einpresswi... |
| 07.07.2023 | FDA Grants Traditional Approval for LEQEMBI® (lecanemab-irmb... | /EIN News/ -- The first and only approved treatment shown to reduce the rate of disease progression ... | einpresswi... |
| 30.06.2023 | New Data at Cure SMA Highlight Potential Benefit of SPINRAZA... | Interim results from the RESPOND study show improved motor function in most participants treated wit... | einpresswi... |
| 13.06.2023 | A 53-year-old biotech investor is set to be replaced by a 32... | Inside a Biogen laboratory. Biogen said biotech exec Susan Langer was nominated to its board. Biogen... | businessin... |
| 09.06.2023 | FDA Advisory Committee Votes Unanimously to Confirm the Clin... | /EIN News/ -- Peripheral and Central Nervous System Drugs Advisory Committee voted based on data fro... | einpresswi... |
| 31.03.2023 | EISAI PRESENTED NEW ANALYSES OF ARIA AND QOL ON LECANEMAB IN... | TOKYO and CAMBRIDGE, Mass., March 30, 2023 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO... | einpresswi... |
| 31.03.2023 | Additional Detailed Analyses From Phase 2 Study 201 of Lecan... | TOKYO and CAMBRIDGE, Mass., March 30, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo,... | einpresswi... |
| 30.03.2023 | Additional Detailed Analyses From Phase 2 Study 201 of Lecan... | /EIN News/ -- TOKYO and CAMBRIDGE, Mass., March 30, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headqu... | einpresswi... |
| 30.03.2023 | Eisai Presented New Analyses of ARIA and QOL on Lecanemab in... | /EIN News/ -- TOKYO and CAMBRIDGE, Mass., March 30, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headqu... | einpresswi... |
| 23.03.2023 | Biogen Provides Update on FDA Advisory Committee Meeting on ... | SOD1-ALS is a rare genetic form of the disease affecting approximately 330 people in the United Stat... | einpresswi... |
| 06.03.2023 | FDA Accepts Eisai's Filing of a Supplemental Biologics Licen... | Confirmatory Phase 3 Clarity AD data to be evaluated by FDA in determining whether to convert accele... | einpresswi... |
| 05.03.2023 | FDA Accepts Eisai’s Filing of a Supplemental Biologics Licen... | /EIN News/ -- Confirmatory Phase 3 Clarity AD data to be evaluated by FDA in determining whether to ... | einpresswi... |
| 06.02.2023 | Biogen and Sage Therapeutics Announce FDA Accepts Filing of ... | Zuranolone is being evaluated as a potential 14-day, rapid-acting, once-daily, oral medication to tr... | einpresswi... |
| 07.01.2023 | Eisai Submits Supplemental Biologics License Application to ... | Submission for traditional approval follows FDA accelerated approval of LEQEMBI on the same day, and... | einpresswi... |
| 04.01.2023 | Biogen and Alcyone Therapeutics Announce License and Collabo... | Alcyone’s ThecaFlex DRx™ System is an implantable medical device in development for intrathecal drug... | einpresswi... |
| 23.12.2022 | EISAI INITIATES BLA SUBMISSION OF DATA FOR LECANEMAB IN CHIN... | TOKYO and CAMBRIDGE, Mass., Dec. 22, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO:... | einpresswi... |
| 09.12.2022 | FDA Accepts Biogen Biologics License Application for BIIB800... | /EIN News/ -- CAMBRIDGE, Mass., Dec. 09, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – annou... | einpresswi... |
| 26.10.2022 | New Data at ECTRIMS 2022 Highlight Biogen’s Commitment to Ad... | Final safety and efficacy results from the Phase 3 EVOLVE-MS-1 trial demonstrate decreases in diseas... | globenewsw... |
| 26.10.2022 | Biogen Data at ECTRIMS 2022 Highlight Innovation in Digital ... | Data demonstrate potential of Manual Dexterity Test and Konectom™ smartphone-based technology in mea... | globenewsw... |
| 17.10.2022 | Biogen Announces FDA’s 3-Month Extension of Review Period fo... | The new Prescription Drug User Fee Act (PDUFA) action date set by the FDA is April 25, 2023
CAMBRIDG... | globenewsw... |
| 03.10.2022 | Biogen and Denali Therapeutics Announce Initiation of the Ph... | Global Phase 3 study to evaluate efficacy and safety of BIIB122, a small molecule inhibitor of LRRK2... | globenewsw... |
| 30.09.2022 | Biogen Announced EMA Filing Acceptance of BIIB800, A Biosimi... | CAMBRIDGE, Mass., Sept. 30, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced that the E... | globenewsw... |
| 21.09.2022 | The New England Journal of Medicine Publishes Pivotal Tofers... | Publication includes the Phase 3 VALOR SOD1-ALS trial and its open-label-extension study, underscori... | globenewsw... |
| 07.09.2022 | The New England Journal of Medicine Publishes Second Manuscr... | Part A results from the two-part Phase 2 LILAC study show litifilimab significantly reduced disease ... | globenewsw... |
| 28.07.2022 | The New England Journal of Medicine Publishes Positive Phase... | Results from Phase 2 LILAC study showed litifilimab significantly reduced skin disease activity in p... | globenewsw... |
| 26.07.2022 | FDA Accepts Biogen’s New Drug Application and Grants Priorit... | SOD1-ALS is a rare genetic form of ALS that affects approximately 330 people in the U.S.,1 it is pro... | globenewsw... |
| 21.06.2022 | European Patent Office Grants Patent Related to TECFIDERA® (... | Patent covers approved dosing regimen for TECFIDERA and expires in 2028
CAMBRIDGE, Mass., June 21, 2... | globenewsw... |
| 15.06.2022 | New Data Presented at Cure SMA Reveal Residual Unmet Needs i... | RESPOND study is actively enrolling, with baseline characteristics reporting infants and toddlers ha... | globenewsw... |
| 14.06.2022 | The Biogen Foundation and Community Lab Celebrates 20 Years ... | The Biogen Foundation has granted $70 million to help underserved communities in advancing science e... | globenewsw... |
| 06.06.2022 | Biogen and Alectos Therapeutics Announce License and Collabo... | Cambridge, Mass. and Burnaby, British Columbia , June 06, 2022 (GLOBE NEWSWIRE) -- Biogen and Alecto... | globenewsw... |
| 06.06.2022 | Biogen and Alectos Therapeutics Announce License and Collabo... | AL01811 is a preclinical selective GBA2 inhibitor with first-in-class potential as an oral disease m... | globenewsw... |
| 03.06.2022 | New 12-Month Tofersen Data Presented at ENCALS Meeting Show ... | 12-month data show that earlier initiation of tofersen slowed decline across measures of clinical an... | globenewsw... |
| 13.05.2022 | The man behind ‘value-based pricing’ saw pharma distorting h... | When Biogen announced the price for Aduhelm, its controversial Alzheimer’s drug, the explanation the... | statnews.c... |
| 05.05.2022 | Biogen and MedRhythms to Develop and Commercialize a Prescri... | The investigational prescription digital therapeutic uses a combination of sensors, software, and mu... | globenewsw... |
| 04.04.2022 | New Data at AAN 2022 Highlight Real-World Evidence from Biog... | Data from NOVA study further support the efficacy and safety of natalizumab IV when administered eve... | globenewsw... |
| 30.03.2022 | Biogen Submits Final Protocol for ADUHELM® (aducanumab-avwa)... | Confirmatory trial’s completion is expected in an accelerated timeline of four years with patient sc... | globenewsw... |
| 28.03.2022 | Biogen and Ionis Announce Topline Phase 1 Study Results of I... | BIIB078, an investigational antisense oligonucleotide for C9orf72-associated amyotrophic lateral scl... | globenewsw... |
| 16.03.2022 | Long-Term Phase 3 Data Show ADUHELM® Continues to Reduce Und... | ADUHELM continued to reduce two key Alzheimer’s disease pathologies, amyloid beta plaques and p-tau1... | globenewsw... |
| 16.03.2022 | Biogen Announces Peer-Reviewed Publication of ADUHELM® Phase... | CAMBRIDGE, Mass., March 16, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced that The J... | globenewsw... |
| 15.03.2022 | Brain+ and Biogen preparing for commercialization in Germany... | Brain+ and Biogen preparing for commercialization in Germany, the #1 EU market for digital therapeut... | news.cisio... |
| 14.03.2022 | Biogen Announces New Updates Across its SMA Research Program... | First patient treated in the ASCEND study evaluating the potential benefit of investigational higher... | globenewsw... |
| 14.03.2022 | Biogen and Eisai amend collaboration agreements on Alzheimer... | Aducanumab collaboration to convert from Eisai sharing of global profits and losses to a global roya... | globenewsw... |
| 11.03.2022 | Biogen to Present New Research at the International Conferen... | CAMBRIDGE, Mass., March 11, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced the compan... | globenewsw... |
| 07.02.2022 | Biogen and Xbrane Announce Commercialization and License Agr... | CAMBRIDGE, Mass and SOLNA, Sweden, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and ... | globenewsw... |
| 01.02.2022 | Biogen Exercises Option to Participate in the Development an... | Mosunetuzumab is an investigational T-cell engaging bispecific antibody targeting CD20 and CD3 in de... | globenewsw... |
| 31.01.2022 | Biogen Announces Nancy Leaming and Brian Posner to Retire fr... | CAMBRIDGE, Mass., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that ... | globenewsw... |
| 28.01.2022 | Biogen Reaches Agreement with Samsung Biologics to Sell Equi... | The companies will continue with their exclusive agreements, including for commercialization of thei... | marketscre... |
| 27.01.2022 | Biogen Reaches Agreement with Samsung Biologics to Sell Equi... | CAMBRIDGE, Mass., Jan. 27, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that ... | globenewsw... |
| 04.01.2022 | Biogen Exercises Option with Ionis to Develop and Commercial... | BIIB115 is a preclinical investigational antisense oligonucleotide (ASO) that may have the potential... | globenewsw... |
| 22.12.2021 | Japan’s First Committee on New Drugs of The Pharmaceutical A... | CAMBRIDGE, Mass., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Eisai Co., Ltd. (... | globenewsw... |
| 20.12.2021 | Biogen Announces Reduced Price for ADUHELM® to Improve Acces... | CAMBRIDGE, Mass., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that,... | globenewsw... |
| 17.12.2021 | Update on Regulatory Submission for Aducanumab in the Europe... | CAMBRIDGE, Mass., Dec. 17, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Eisai Co., Ltd. (... | globenewsw... |
| 16.12.2021 | Update on the Phase 4 Confirmatory Study of ADUHELM® | CAMBRIDGE, Mass., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Eisai Co., Ltd. (... | globenewsw... |
| 14.12.2021 | Biogen and TheraPanacea Announce New Collaboration with the ... | Collaboration aims to develop innovative machine learning and artificial intelligence solutions for ... | globenewsw... |
| 17.11.2021 | Update on Regulatory Review of Aducanumab in the European Un... | CAMBRIDGE, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Eisai Co., Ltd. (... | globenewsw... |
| 16.11.2021 | Biogen Announces Alfred W. Sandrock, Jr. to Retire as Head o... | CAMBRIDGE, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced today that ... | marketscre... |
| 16.11.2021 | The European Commission Grants Marketing Authorization for V... | VUMERITY is a next-generation oral fumarate treatment for people with relapsing-remitting MS with es... | globenewsw... |
| 15.11.2021 | Biogen Announces Alfred W. Sandrock, Jr. to Retire as Head o... | CAMBRIDGE, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced today that ... | globenewsw... |
| 15.11.2021 | Biogen Sets Industry Record with Recognition on Dow Jones Su... | Biogen earns top ESG leadership scores on areas including Innovation Management and Climate Strategy... | globenewsw... |
| 11.11.2021 | New Phase 3 Data Show Positive Correlation Between ADUHELM™ ... | In a pre-specified analysis, ADUHELM significantly lowered plasma p-tau181, a biomarker of the hallm... | globenewsw... |
| 10.11.2021 | Eisai Presents Late-Breaker Updates on Lecanemab Clinical, B... | TOKYO and CAMBRIDGE, Mass, Nov. 10, 2021 - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, &... | marketscre... |
| 10.11.2021 | Eisai Presents Late-Breaker Updates On Lecanemab Clinical, B... | TOKYO and CAMBRIDGE, Mass., Nov. 10, 2021 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO:... | marketscre... |
| 03.11.2021 | Biogen Announces Late Breakers and Additional New Data Prese... | Late breaker will show ADUHELM™ effect on plasma pTau181 reduction, and its correlation with amyloid... | globenewsw... |
| 17.10.2021 | Biogen Announces Topline Results from the Tofersen Phase 3 S... | In the Phase 3 VALOR study, the primary endpoint as measured by the Revised Amyotrophic Lateral Scle... | globenewsw... |
| 14.10.2021 | Topline Results from Tofersen Phase 3 Study and its Open Lab... | CAMBRIDGE, Mass., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced topli... | globenewsw... |
| 13.10.2021 | New Data at ECTRIMS 2021 Highlight Biogen’s Focus on Patient... | Full analysis of Phase 3b NOVA study provides insights on efficacy of every six-week dosing with nat... | globenewsw... |
| 13.10.2021 | New MS PATHS Data at ECTRIMS 2021 Confirm Biogen’s Disease-M... | MS PATHS data indicate that 100 percent of people with MS treated with natalizumab, interferons or f... | globenewsw... |
| 15.09.2021 | Biogen : Announces Agenda for Virtual Investor Day R&D D... | CAMBRIDGE, Mass. - September 15, 2021 - Biogen Inc.(Nasdaq: BIIB) today announced the agenda for its... | marketscre... |
| 12.08.2021 | QAD : ERP Aids Your Sustainability Initiatives | Sustainable manufacturing refers to the ability to manage manufacturing operations 'in an environmen... | marketscre... |
| 30.07.2021 | Biogen : Late-Breaking AAIC Presentation Explores Potential ... | Eisai and Biogen Present Preliminary Assessment of the Clinical Effects of Lecanemab Following
18 Mo... | marketscre... |
| 30.07.2021 | Eisai : LATE-BREAKING AAIC PRESENTATION EXPLORES POTENTIAL C... | For Print
July 30, 2021
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, 'Eisai') and Biogen ... | marketscre... |
| 29.07.2021 | Biogen : Late-Breaking AAIC Presentation Explores Potential ... | TOKYO, July 29, 2021 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "E... | marketscre... |
| 26.07.2021 | Biogen : and Ionis report positive topline clinical data on ... | Phase 1b study of BIIB080/IONIS-MAPTRx met primary objective of safety and tolerability
Study demons... | marketscre... |
| 16.06.2021 | BIOGEN INC.
Biogen Announces Topline Results From Phase 2 S... | CAMBRIDGE, Mass., June 16, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced topli... | marketscre... |
| 15.06.2021 | Sage Therapeutics and Biogen Announce Positive Pivotal Phase... | At the Day 15 primary endpoint, zuranolone 50 mg showed a statistically significant and clinically m... | marketscre... |
| 14.06.2021 | BIOGEN INC.
Biogen Announces Topline Results from Phase 3 G... | The Phase 3 STAR study did not meet primary or key secondary endpoints
Choroideremia is a rare inher... | marketscre... |
| 25.05.2021 | BIOGEN INC.
Biogen : Announces Webcast of Annual Meeting of... | Cambridge, Mass. - Biogen Inc. (Nasdaq: BIIB) announced today that the webcast of the Company's 2021... | marketscre... |
| 23.05.2021 | Biogen and Ginkgo Bioworks Sign Gene Therapy Collaboration | Neuroscience company Biogen (Nasdaq: BIIB) and Ginkgo Bioworks, a developer of a platform to program... | finsmes.co... |
| 14.05.2021 | BIOGEN INC.
Biogen Announces Topline Results From Phase 2/3... | While the Phase 2/3 XIRIUS study did not meet its primary endpoint, data indicated positive trends i... | marketscre... |
| 12.05.2021 | BIOGEN INC.
Biogen Announces Exercise of Option to Acquire ... | TMS-007 has the potential to be a next generation thrombolytic with an improved benefit-risk profile... | marketscre... |
| 27.04.2021 | Biogen to expand access to its ALS drug, but move may come t... | After weeks of controversy, Biogen (BIIB) has agreed to provide an experimental drug for combating A... | statnews.c... |
| 22.04.2021 | Biogen : Reports Q1 2021 Earnings | BIOGEN REPORTS FIRST QUARTER 2021 RESULTS
First quarter revenue $2,694 million; GAAP diluted EPS $2.... | marketscre... |
| 22.04.2021 | BIOGEN INC.
Biogen : Reports Q1 2021 Earnings | BIOGEN REPORTS FIRST QUARTER 2021 RESULTS
First quarter revenue $2,694 million; GAAP diluted EPS $2.... | marketscre... |
| 22.04.2021 | BIOGEN INC.
Biogen : Reports First Quarter 2021 Results | BIOGEN REPORTS FIRST QUARTER 2021 RESULTS
First quarter revenue $2,694 million; GAAP diluted EPS $2.... | marketscre... |
| 22.04.2021 | Biogen : Reports First Quarter 2021 Results | BIOGEN REPORTS FIRST QUARTER 2021 RESULTS
First quarter revenue $2,694 million; GAAP diluted EPS $2.... | marketscre... |
| 19.04.2021 | BIOGEN INC.
Biogen Advances Leading Research in Spinal Musc... | Initial findings from the DEVOTE study suggest no new safety concerns and support continued developm... | marketscre... |
| 07.04.2021 | BIOGEN INC.
The European Commission Grants Marketing Author... | TYSABRI is a well-established high-efficacy treatment that now provides two routes of administration... | marketscre... |
